The trial was conducted to study whether adenosine monophosphate protein kinase （AMPK） could regulate the cholesterin reduction effect of lovastatin which was metabolic product of cholesterin in laying hens. Twenty 47-week-old new Roman laying hens were allotted to two groups with five replicates in each group and two hens in each replicate. Laying hens were fed the basal diet (control group) and the trial diet which added 0.06% lovastatin in the basal diet, respectively. The trial lasted for 3 weeks. The results showed that: 1) 0.06% lovastatin could maintain performance of laying hens and reduce the cholesterin content of eggs. Compared with control group, the cholesterin content of egg yolk (mg/g egg yolk) reduced 11.56%, 10.88% and 12.75% in the first, second and third week, respectively （P<0.05）; and the cholesterin content of whole egg yolk (mg/yolk) reduced 16.01%, 17.95% and 19.79% （P<0.05） in the first, second and third week, respectively; 2) 0.06% lovastatin could increase the activity of AMPK by 5.69% （P>0.05） and reduce the activities of β-hydroxy-β-methylglutary-CoA reductas (HMGR) and acetyl-CoA carboxylase (ACC) by 2189% （P<0.05） and 9.72% （P>0.05） in the liver of laying hens, respectively; 3) cell culture fluid added with 0.3 mmol/L lovastatin could enhance the activity of AMPK by 5.02% in liver cells of laying hens （P>0.05）; compared with which added with 0.3 mmol/L lovastatin, cell culture fluid added with both 0.3 mmol/L lovastatin and 0.5 mmol/L Br8-AMP (AMPK inhibitor) could reduce the activity of AMPK by 4.57% （P>0.05）. It was concluded that the cholesterin reduction effect of lovastatin may be mediated by AMPK partly.